Logo1 logo2
Attention Investors
Kindly note the Change in PAY IN for BSE A/C No. : 1201250000000691 (CDSL), if you have an NSDL A/C, kindly use INTER DEPOSITORY SLIP. For assistance, please call OR contact: Mr. Dadu, 98339 89807 / 022-6145 1000.    |   Exchanges / Depository: Prevent Unauthorized Transactions in your Trading / Demat account --> Update your Mobile Numbers / email IDs with your Stock Brokers / Depository Participant. Receive alerts on your Registered Mobile / email IDs for trading account transactions and all debit and other important transactions in your demat account directly from Exchange / Depository on the same day ......................Issued in the interest of Investors."     |    KYC : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."     |    ASBA-IPO : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
tiker sep
plus stop minus
 
 
Parmax Pharma LtdIndustry : Pharmaceuticals - Indian - Bulk Drugs
BSE Code:540359NSE Symbol: Not ListedP/E(TTM):0
ISIN Demat:INE240T01014Div & Yield %:0EPS(TTM):0
Book Value(Rs):-18.3323978Market Cap (rupee Cr.):18.26Face Value(Rs):10
    Change Company 
Date Headline
04-Jun-26 Parmax Pharma to hold board meeting
04-Jun-26 Parmax Pharma reports standalone net loss of Rs0.58 crore in the March 2026 quarter
02-Jun-26 Parmax Pharma revises board meeting date
30-May-26 Parmax Pharma revises board meeting date
29-May-26 Parmax Pharma to discuss results
05-May-26 Parmax Pharma schedules EGM
15-Feb-26 Parmax Pharma reports standalone net loss of Rs0.73 crore in the December 2025 quarter
11-Feb-26 Parmax Pharma to announce Quarterly Result
18-Nov-25 Parmax Pharma reports standalone net loss of Rs2.08 crore in the September 2025 quarter
11-Nov-25 Parmax Pharma announces board meeting date
<< < 1 2 > >>